The Company has completed enrollment of Phase I and Phase II trials of its Skeletal Targeted Radiation product, combined with chemotherapy in patients with multiple myeloma. The Company is also developing a proprietary Pretarget platform for the delivery of therapeutic products to tumor sites. NeoRx completed a pilot Phase I trial in 1999 using its Pretarget technology for the treatment of lymphoma. NeoRx is currently making additional fusion proteins that may potentially be used to treat cancers other than lymphoma.
Revenues reflect the inclusion of revneues from patent licensing agreements.
Market Guide offers more in-depth Company Research , Stock Screening , and Hottest Stocks and Industries on over 10,000 U.S. Equities. All Rights Reserved. Privacy Policy - Terms of Service Company information Copyright Market Guide . Some event data provided by StreetEvents . Data and information is provided for informational purposes only, and is not intended for trading purposes.